APG Asset Management N.V. Purchases 4,949 Shares of Illumina, Inc. (NASDAQ:ILMN)

APG Asset Management N.V. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 86,768 shares of the life sciences company’s stock after purchasing an additional 4,949 shares during the period. APG Asset Management N.V. owned about 0.05% of Illumina worth $8,451,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Illumina by 0.4% during the first quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock valued at $2,505,409,000 after buying an additional 66,528 shares during the last quarter. Baillie Gifford & Co. grew its holdings in Illumina by 8.7% during the 1st quarter. Baillie Gifford & Co. now owns 5,736,418 shares of the life sciences company’s stock valued at $787,725,000 after buying an additional 460,649 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Illumina by 7.2% in the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock worth $317,267,000 after buying an additional 204,043 shares in the last quarter. Capital World Investors grew its position in shares of Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after purchasing an additional 801,814 shares in the last quarter. Finally, Primecap Management Co. CA increased its stake in Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after acquiring an additional 1,997,010 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Illumina stock opened at $130.12 on Monday. The company has a 50-day moving average price of $126.36 and a 200 day moving average price of $120.26. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $148.19. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The stock has a market cap of $20.73 billion, a P/E ratio of -15.97 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the firm posted $0.32 EPS. Illumina’s revenue for the quarter was down 5.4% on a year-over-year basis. Sell-side analysts anticipate that Illumina, Inc. will post 3.63 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Robert W. Baird boosted their target price on Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. TD Cowen raised shares of Illumina from a “hold” rating to a “buy” rating and boosted their price objective for the company from $126.00 to $144.00 in a research report on Wednesday, August 14th. Piper Sandler lowered their price objective on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a research note on Friday, August 16th. Finally, Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $152.05.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.